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Abstract
Background: Lung cancer is the leading cause of cancer mortality worldwide. Tobacco smoking
is its primary cause, and yet the precise molecular alterations induced by smoking in lung tissue that
lead to lung cancer and impact survival have remained obscure. A new framework of research is
needed to address the challenges offered by this complex disease.
Methods/Design: We designed a large population-based case-control study that combines a
traditional molecular epidemiology design with a more integrative approach to investigate the
dynamic process that begins with smoking initiation, proceeds through dependency/smoking
persistence, continues with lung cancer development and ends with progression to disseminated
disease or response to therapy and survival. The study allows the integration of data from multiple
sources in the same subjects (risk factors, germline variation, genomic alterations in tumors, and
clinical endpoints) to tackle the disease etiology from different angles. Before beginning the study,
we conducted a phone survey and pilot investigations to identify the best approach to ensure an
acceptable participation in the study from cases and controls. Between 2002 and 2005, we enrolled
2101 incident primary lung cancer cases and 2120 population controls, with 86.6% and 72.4%
Published: 6 June 2008
BMC Public Health 2008, 8:203 doi:10.1186/1471-2458-8-203
Received: 22 October 2007
Accepted: 6 June 2008
This article is available from: http://www.biomedcentral.com/1471-2458/8/203
© 2008 Landi et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Public Health 2008, 8:203 http://www.biomedcentral.com/1471-2458/8/203
Page 2 of 10
(page number not for citation purposes)
participation rate, respectively, from a catchment area including 216 municipalities in the Lombardy
region of Italy. Lung cancer cases were enrolled in 13 hospitals and population controls were
randomly sampled from the area to match the cases by age, gender and residence. Detailed
epidemiological information and biospecimens were collected from each participant, and clinical
data and tissue specimens from the cases. Collection of follow-up data on treatment and survival
is ongoing.
Discussion: EAGLE is a new population-based case-control study that explores the full spectrum
of lung cancer etiology, from smoking addiction to lung cancer outcome, through examination of
epidemiological, molecular, and clinical data. We have provided a detailed description of the study
design, field activities, management, and opportunities for research following this integrative
approach, which allows a sharper and more comprehensive vision of the complex nature of this
disease. The study is poised to accelerate the emergence of new preventive and therapeutic
strategies with potentially enormous impact on public health.
Background
Lung cancer, the largest single cause of cancer mortality in
the U.S. and worldwide, kills more people every year than
cancers of the breast, prostate and colon combined. The
SEER registry estimated that 213,380 new cases and
160,390 deaths would occur in the US in 2007 [1]; age-
standardized incidence rates across European countries in
2005 [2] varied between 21 and 77 per 100,000 in men
and 3 and 35 in women, with age-standardized mortality
rates ranging between 32 and 52 per 100,000 in men and
between 8 and 19 per 100,000 in women. Traditional
approaches to treatment, screening and prevention of
lung cancer are inadequate, and there is currently no effec-
tive chemoprevention or proven effective screening for
this disease. Newer molecular targeted chemotherapeutic
agents result in short-term improvements in survival in
responsive subsets, but have had marginal impact on
overall mortality.
Epidemiological and other scientific investigations have
clearly implicated tobacco smoking as the primary cause
of lung cancer, and yet the precise molecular alterations
induced by smoking in lung tissue that lead to lung cancer
and impact survival have remained obscure. Many lines of
evidence consistently support a hereditary influence on
lung cancer risk, with polygenic mechanisms and complex
interactions, including epistatic relationships [3]. Over
100 studies have examined individual candidate genes in
relation to lung cancer during the last decade. Despite this
body of literature, no clear consensus exists on the role
these factors play in influencing lung cancer susceptibility.
The vast majority of published studies in this field have
been underpowered in relation to the realistic main and
interactive effects suggested by recent metanalyses [4-6].
In addition, they have been focused only on a few genes
or few risk factors, whereas many genes and interactions
between genes and other risk factors are likely important
for lung carcinogenesis.
We designed a large population-based case-control study
precisely to combine a traditional molecular epidemiol-
ogy design with a more integrative approach to investigate
the effects of a dynamic process that begins with smoking
initiation, proceeds through dependency and smoking
persistence, continues with lung cancer development and
ends with progression to disseminated disease or response
to therapy and survival.
This approach maximizes the use of epidemiological, clin-
ical, behavioral, and molecular data from the same sub-
jects to answer multiple questions at the same time. For
example, we supplemented the detailed information on
smoking and family history of lung cancer needed for the
etiologic study with additional information on behavioral
factors and family history of smoking from the first degree
relatives of cases and controls. This allows study of genetic
determinants of persistence or cessation of smoking in
controls and enhances our ability to assess the effect of
shared familial tobacco use on the putative genetic effect
of family history of lung cancer on lung cancer risk. We
supplemented collection of blood specimens needed to
study genetic variation on susceptibility to lung cancer
with fresh frozen lung tissue samples to study whether
these germ-line variations (with or without smoking
exposure) are associated with altered expression of these
same genes and related pathways in the target organ. We
supplemented detailed pathology information from each
lung cancer case needed to assess etiologic heterogeneity
with collection of treatment and outcome data to learn
about disease progression and efficacy of treatment.
The Environment And Genetics in Lung cancer Etiology
(EAGLE) study is an integrative population-based study of
lung cancer. We present here the study design, field activ-
ities, management organization, strategies we used to
increase the participation rate in population controls, and
characteristics of the enrolled subjects. We also provide
our perspectives on how the integration of complex epide-BMC Public Health 2008, 8:203 http://www.biomedcentral.com/1471-2458/8/203
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miological, clinical and genomic data and participation of
multiple investigators can shed light on the etiology, pre-
vention and treatment of this deadly disease.
Methods
Study Design
The study was conducted in the Lombardy region of Italy,
which includes approximately 9,600,000 people and is
served by a network of modern hospitals, medical
schools, and a regional health service. The catchment area
includes 5 cities (Milan, Monza, Brescia, Pavia, and Var-
ese) and surrounding towns and villages, for a total of 216
municipalities, encompassing over 3,000,000 people. The
theoretical ideal is random collection of cases from the
population, e.g., through a cancer registry. However, ran-
dom selection from hundreds of large and small hospitals
would have made collection of biospecimens (particu-
larly fresh frozen tissue samples) and detailed epidemio-
logical and clinical data unfeasible. Thus, we designed
EAGLE to be as close as possible to a really comprehensive
population-based study through enrollment of cases in a
defined set of hospitals, which examine approximately
80% of all lung cancer cases from the catchment area.
These hospitals were selected based on a review of the
hospital admission/discharge records from the years
1997–2000.
EAGLE includes 2101 verified, incident, primary lung can-
cer cases of any histologic type, with the exception of car-
cinoids, and 2120 healthy population-based controls.
Participants are both male and female, born in Italy, of
Italian nationality, and with official residence in the 216
selected municipalities, at ages between 35 and 79 years
old at diagnosis (cases) or enrollment for interview (con-
trols) that signed an informed consent form to participate
in the study. The study was approved by the Institutional
Review Board (IRB) of each participating hospital and
university in Italy and by the National Cancer Institute,
Bethesda, MD.
EAGLE's study size is powered to detect small increases in
risk for factors with moderate frequency; for example the
power is at least 80% to detect an association between a
given genotype and lung cancer risk with an OR of 1.4 for
at-risk genotype frequency between 10% and 90%. Under
a multiplicative gene-environment interaction model, the
study is large enough to reject at a 0.05-level with 80 per-
cent power an interaction of 0.5 between the highest
smoking category relative to the non-smoking category
when the at-risk genotype frequency is > 13%, and of 0.2,
if the at-risk genotype frequency is 5% or higher and the
distributions of smoking and the gene are independent
[7].
Lung cancer cases
We recruited cases from thirteen hospitals. A detailed
description and link to the respective hospitals is available
on the EAGLE website [8]. The first diagnosis of all lung
cancer cases occurred in the period between April 22nd,
2002 and February 28th, 2005, and enrollment continued
until June 30th, 2005. Two research physicians per hospi-
tal reviewed daily hospital admission logs in different
departments, identified cases of suspected lung cancer in
the specified age range and from the catchment area, and
arranged for collection of blood specimens and for subject
interview. Rapid communication with the central institute
from each hospital was performed using a web-based
case-registry connected through dedicated Integrated Serv-
ices Digital Network (ISDN) lines. Reasons for non-eligi-
bility were recorded for all subjects. Subjects who declined
to participate were asked to answer a few questions on
smoking and demographic characteristics that allowed us
to obtain a more comprehensive picture of the lung cancer
cases of the area within the study period.
The diagnosis of lung cancer was established based on
clinical criteria and confirmed by pathology reports from
surgery, biopsy or cytology samples in approximately
95% of cases, and on clinical history and imaging for the
remaining 5%. The date of diagnosis was defined as the
date of the first clinical study to report a suspicious lesion
(for example, chest X-ray or CT-scan) that led directly to
diagnosis. To verify the diagnosis, we examined the clini-
cal history, bronchoscopy and biopsy results, and x-ray
and thorax CT scans (and MRI or PET scans when availa-
ble) and hospital discharge letter for each case. In addi-
tion, we reviewed surgery descriptions and pathology
reports for the surgical cases, and biopsies and/or cytology
reports from brushing, broncho-alveolar lavage, sputum,
bronchoaspirate, or pleural or pericardial effusion for the
non-surgical cases. All available imaging documenting
lymph node and/or distant metastases or other func-
tional/clinical conditions that excluded surgery were also
assessed. Tumor histology was coded according to the
WHO Histological Typing of Lung and Pleural Tumors
(1999); clinical and/or post-surgical staging was per-
formed according to the International System for Staging
Lung Cancer adopted by the American Joint Committee
on Cancer and the Union Internationale Contre le Cancer
[9]. To verify extra-thorax metastases, we reviewed
abdominal CT scans and ultrasounds, brain CT scans or
MRI, and bone scintigraphy scans. To standardize diag-
nostic criteria across hospitals we reviewed clinical docu-
mentation and when necessary made changes to the
original diagnosis/staging; in these instances the reason
and the specific changes made were documented in a deci-
sion log. Diagnoses from approximately 10% of cases
were reviewed and confirmed by an experienced inde-BMC Public Health 2008, 8:203 http://www.biomedcentral.com/1471-2458/8/203
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pendent pulmonary pathologist from the National Can-
cer Institute, NIH (Dr. Ilona Linnoila).
At study completion, we had screened 4630 subjects of
whom over 2706 were eligible based on the inclusion cri-
teria. We enrolled 2343 cases (86.6% of the eligible cases),
of whom 179 (7.6%) were determined not to have lung
cancer after diagnosis review; an additional 63 subjects
had an uncertain diagnosis or were determined not to fit
the inclusion criteria. Thus, subjects with confirmed diag-
nosis and characteristics fitting the inclusion and exclu-
sion criteria were 2101. Epidemiological data and DNA
specimens were collected from 98.4% and 97.3% of cases,
respectively (Table 1).
The distribution of EAGLE lung cancer cases by area of res-
idence, gender and age (matching variables) is reported in
Table 2; the distribution by cigarette smoking, histology
and stage is reported in Tables 3A and 3B for females and
males, respectively.
Population controls
The population with official residence in the catchment
area represented the study pool from which controls were
sampled. The Regional Health Service (RHS) database
contains information on subjects' demographics and on
the family physician for virtually all Italians. We sampled
population controls from updated population databases
obtained periodically (twice a year) from the Lombardy
Region; the age of controls was calculated as of pre-speci-
fied dates, i.e., July 22nd and January 22nd of each year.
Controls were selected randomly within 90 cells (see
below) to yield a set of controls with a distribution that
initially approximated the case distribution based on year
2000 lung cancer admissions, and subsequently was
based on enrolled EAGLE lung cancer cases, for 3 key var-
iables: residence (5 areas: Brescia, Milan, Monza, Pavia,
Varese), gender, and five-year age classes in the range 35–
79 years (5 × 2 × 9 combinations of residence-gender-age
categories). To select controls, a random number was
assigned to each subject using statistical software, and the
records were sorted based on this random number. Each
subject with a number below the target enrollment
number for the individual's cell was selected to be invited
into the study. The family physicians for the potential
study subjects were identified. The selected physicians
were then asked to provide information about eligibility
of the potential study subjects and, if eligible, to contact
the selected controls to inform them about the study. Eli-
gible controls were contacted by letter from the study per-
sonnel, followed by a phone call. When the phone
Table 1: Distribution of questionnaire data and biological samples in cases and controls from EAGLE
Cases No. 2101 Controls No. 2120
No. % No. %
With data on major risk factors 2067 98.4 2116 99.8
With data on diet and behavioural factors 1903 90.6 2073 97.8
With at least one DNA sample* 2045 97.3 2117 99.9
With blood sample 1891 90.0 1841 86.8
With buccal rinse sample 154 7.3 282 13.3
With at least one pathology sample 1212 57.7
With tissue slides 1192 56.7
With paraffin-embedded tissue blocks 656 31.2
With fresh tissue samples 436 20.8
*Two cases and six controls donated both blood and buccal samples
Table 2: Population in the catchment area* and distribution of 
EAGLE subjects by gender, age, and residence (matching 
variables)
Population Cases Controls
No. % No. % No. %
Area
Brescia 272,786 16.6 275 13.1 248 11.7
Milan 963,341 58.7 1369 65.2 1440 67.9
Monza 155,491 9.5 144 6.8 117 5.5
Pavia 122,036 7.4 137 6.5 130 6.1
Varese 128,420 7.8 176 8.4 185 8.7
Gender
Females 867,310 52.8 449 21.4 500 23.6
Males 774,764 47.2 1652 78.6 1620 76.4
Age
35–39 242,876 14.8 12 0.6 17 0.8
40–44 203,923 12.4 19 0.9 28 1.3
45–49 185,568 11.3 52 2.5 71 3.3
50–54 206,127 12.6 133 6.3 127 6.0
55–59 183,214 11.2 240 11.4 300 14.1
60–64 196,734 12.0 359 17.1 371 17.5
65–69 167,764 10.2 474 22.6 489 23.1
70–74 143,191 8.7 471 22.4 424 20.0
75–79 112,677 6.9 341 16.2 293 13.8
Total 1,642,074 100.0 2101 100.0 2120 100.0
*N = 216 municipalities, 2001 census; age 35–79 years.BMC Public Health 2008, 8:203 http://www.biomedcentral.com/1471-2458/8/203
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Table 3: Distribution of EAGLE lung cancer cases by cigarette smoking*, histology and stage in females and males.
A – Females
Never Former Current Missing Total
No. % No. % No. % No. % No. %
Histology
Non small cell lung carcinoma (NSCLC) 101 87.8 96 78.0 146 73.0 10 90.9 353 78.6
Adenocarcinoma 85 73.9 64 52.0 90 45.0 5 45.4 244 54.3
Squamous cell 7 6.1 19 15.4 22 11.0 1 9.1 49 10.9
Large cell 2 1.7 6 4.9 12 6.0 0 - 20 4.5
NSCLC, not defined 7 6.1 7 5.7 22 11.0 4 36.4 40 8.9
Small cell carcinoma 3 2.6 8 6.5 29 14.5 0 0.0 40 8.9
Others (mixed types) 5 4.4 13 10.6 18 9.0 1 9.1 37 8.2
Missing 6 5.2 6 4.9 7 3.5 0 0.0 19 4.2
Stage
0 00 . 000 . 000 . 000 . 0 00 . 0
IA 11 9.6 13 10.6 20 10.0 2 18.2 46 10.2
IB 14 12.2 13 10.6 23 11.5 0 0.0 50 11.1
IIA 0 0.0 3 2.4 3 1.5 1 9.1 7 1.6
IIB 10 8.7 10 8.1 14 7.0 0 0.0 34 7.6
I I I A 1 31 1 . 31 81 4 . 62 61 3 . 0 0 0 . 0 5 71 2 . 7
I I I B 1 81 5 . 61 51 2 . 22 81 4 . 0 32 7 . 3 6 41 4 . 3
IV 48 41.7 50 40.7 81 40.5 5 45.4 184 41.0
X 10 . 910 . 852 . 500 . 0 71 . 6
Total 115 100.0 123 100.0 200 100.0 11 100.0 449 100.0
B – Males
Never Former Current Missing Total
No. % No. % No. % No. % No. %
Histology
Non small cell lung carcinoma (NSCLC) 28 84.9 607 80.0 662 79.0 14 60.9 1311 79.4
Adenocarcinoma 20 60.6 283 37.3 305 36.4 6 26.1 614 37.2
Squamous cell 5 15.2 233 30.7 241 28.8 5 21.7 484 29.3
Large cell 0 0.0 23 3.0 33 3.9 1 4.4 57 3.5
NSCLC, not defined 3 9.1 68 9.0 83 9.9 2 8.7 156 9.4
Small cell carcinoma 1 3.0 73 9.6 100 11.9 2 8.7 176 10.7
Others (mixed types) 1 3.0 39 5.2 38 4.5 2 8.7 80 4.8
Missing 3 9.1 39 5.2 38 4.5 5 21.7 85 5.1
Stage
0 00 . 010 . 100 . 000 . 0 10 . 1
IA 3 9.1 78 10.3 59 7.0 1 4.4 141 8.5
IB 1 3.0 109 14.4 93 11.1 2 8.7 205 12.4
IIA 0 0.0 11 1.4 11 1.3 0 0.0 22 1.3
IIB 4 12.1 65 8.6 76 9.1 1 4.4 146 8.8
IIIA 1 3.0 78 10.3 97 11.6 1 4.4 177 10.7
IIIB 4 12.1 102 13.5 150 17.9 3 13.0 259 15.7
IV 20 60.6 295 38.9 331 39.5 14 60.9 660 40.0
X 0 0.0 19 2.5 21 2.5 1 4.4 41 2.5
Total 33 100.0 758 100.0 838 100.0 23 100.0 1652 100.0
*Never smoking, Former smoking and Current smokingBMC Public Health 2008, 8:203 http://www.biomedcentral.com/1471-2458/8/203
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number for the selected individuals could not be found,
we searched for the phone numbers of other members of
the family identified through contact with the corre-
sponding municipalities, or sent pre-stamped return-cards
requesting contact information.
At study completion we had sent invitation letters fol-
lowed by phone call to 3314 potential controls. Traced eli-
gible subjects were 2774, of whom 2012 accepted to
participate. Completion rate was 60.7% (subjects who
accepted to participate/contacted subjects) and participa-
tion rate was 72.5% (subjects who accepted to participate/
eligible subjects). Moreover, we sent pre-stamped return-
cards to 393 subjects whom we were unable to trace
through the phone. Of these, 155 were eligible, and 108
accepted to participate (completion rate = 27.5%, partici-
pation rate = 69.7%). Overall, we enrolled 2120 controls,
with an overall participation rate of 72.4%. Epidemiolog-
ical data and DNA samples were collected from 99.8%
and 99.9% of controls, respectively (Table 1).
The distribution of EAGLE controls by area of residence,
gender and age (matching variables) is reported in Table
2.
Strategies to improve subjects' participation rate
The strategies we followed for subjects' enrollment
described above were derived from a series of pilot studies
we conducted before officially beginning the EAGLE field
activities. Because determinants of participation in cases
(medical condition, performance status) are different
from the determinants in controls (altruism, time), we
were concerned that lack of participation might affect esti-
mates of genetic or environmental main effects and inter-
actions on lung cancer risk [10-12]. We made concerted
efforts to maximize participation of both cases and con-
trols, and used several strategies and incentives to increase
the participation rate in controls.
First, to verify the feasibility of a population-based study
in the Lombardy region of Italy and study the characteris-
tics related to potential subjects' participation, we con-
ducted a phone survey of 1053 healthy subjects from the
catchment area, selected from the rosters of the Regional
Health Service, to have the age, gender and geographic
distribution expected in the lung cancer cases. We asked
the contacted subjects whether they would agree to partic-
ipate in a study of lung cancer that would require an inter-
view and donation of a blood sample. Only 320 (30%) of
the subjects responded "Yes". There was only modest var-
iation in response by municipality, age, gender, tobacco
use, and educational level. From this effort, we obtained
valuable information about preferred location for blood
drawing, days of the week, and times most convenient for
participation. This information was used in a series of
pilot studies in which we first contacted the selected indi-
viduals by mail with follow-up by telephone, offering par-
ticipation in the study at the closest hospitals of the
catchment area. Then, we advertised the study on the local
TV and in newspapers, and added gas coupons as reim-
bursement for time lost. Subsequently, we proposed con-
ducting the interview in the subjects' homes, and added a
letter endorsing the study signed by the family physician.
These efforts achieved a response rate of 48.9%. To
increase the participation rate further, we consulted with
one of the largest market research companies in Italy, and
implemented the following procedures: we altered the
layout of the invitation letter, established a toll-free phone
number through which potential participants could
obtain study information, added to our invitation a letter
from the mayor of Milan supporting our research project,
and requested that family physicians call the subjects
directly to inform them about the seriousness and scien-
tific value of the study. We also provided a token of grati-
tude (gas coupon) to the physicians. With these measures,
we achieved an acceptable response rate of 72%. Overall,
in the pilot studies, we collected data on approximately
300 subjects. This level of response remained constant
through the course of the full-scale study.
Impact of incentives on participation rate and enrolled 
subjects' characteristics
After study completion, we assessed the impact of the
involvement of the family physician in controls' response
rate. Controls contacted by their family physician had a
much higher participation rate (80.1%) than those
(49.3%) not contacted.
To further evaluate the impact of incentives on study par-
ticipation, we explored the socio-demographic differences
between control subjects who were enrolled with few or
no incentives (~49% response rate) and those who were
enrolled with the improved procedures (~73% response
rate). We included in these analyses all controls recruited
during the pilot studies and those recruited in the main
study up to March 2003 (N = 748). We found some sug-
gestive associations: the high incentive group exhibited an
increased family history of lung cancer (p = 0.03); in addi-
tion, borderline associations were observed for: awareness
of the link between smoking and lung cancer (lower, p =
0.07), anxiety score (lower, p = 0.08) and depression score
(higher, p = 0.13) as measured by the Hospital Anxiety
and Depression Scale (HADS), intention to quit smoking
(lower, p = 0.10), history of quit attempts (lower, p =
0.11), military service (lower frequency, p = 0.11), and
percentage attending college (lower, p = 0.12). Adjust-
ment for age, gender, and, when appropriate, smoking,
did not substantially alter these findings. We also found
small non-significant differences by incentive group in a
panel of 15 short tandem repeat (STR) loci used to iden-BMC Public Health 2008, 8:203 http://www.biomedcentral.com/1471-2458/8/203
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tify genetic differences between samples for quality con-
trol of sample handling and processing [13]. These
analyses suggest that in studies with low response rates,
estimates may be influenced by factors such as family his-
tory, education or behavioral characteristics.
In the pilot studies, we could not verify the efficacy of each
incentive or procedure separately because different types
of incentives were often offered together. We did, how-
ever, ask participants to rank the factors that influenced
their participation. Among the most influential factors
reported by subjects recruited through December 2003,
"desire to help medical research" (78%), "reassured by the
family physician" (53%), and "possibility to participate
from home" (44%) were the most frequent "very high"
scores. "Receiving compensation", "obtaining informa-
tion by calling a toll-free number", and "receiving the let-
ter from the mayor of Milan" were the factors with the
most frequent, "very low" scores (61%, 47%, and 40%,
respectively). The majority of subjects were not aware of
the advertisements about the study that appeared on the
local TV or newspapers. These data are relevant to future
studies, with the caveat that they are based on self-report-
ing in one cultural setting, and need to be evaluated by
direct comparison.
Epidemiological and clinical data collection
Extensive epidemiological data have been collected
through both a Computer Assisted Personal Interview
(CAPI) to capture the major risk factors for lung cancer
and a self-administered questionnaire to address behavio-
ral aspects possibly associated with smoking persistence
and diet (questionnaires are available on the EAGLE web-
site). In particular, data on tobacco smoking included
information on number of cigarettes, cigars, pipes, and
cigarillos per day averaged over lifetime and in the last
year, age at initiation/quit, quitting attempts and time
between attempts, inhalation habits, cigarette/cigar
brand, passive smoking during childhood, at workplace
and at home during adulthood. Moreover, we collected
data on tobacco smoking in first-degree relatives. To
explore the determinants of smoking persistence we also
added key behavioral rating scales including the Fager-
ström Test for Nicotine Dependence (FTND) [14], nico-
tine withdrawal [15], knowledge about smoking effects,
Beck's Depression Inventory, Hospital Anxiety and
Depression Scale (HADS) [16], alcohol dependence,
Attention Deficit Disorder (ADD), and the Short-Form
Revised Eysenck Personality Questionnaire [17]. A limited
food frequency questionnaire evaluated diet for specific
variables of interest: vegetables, fresh and dry fruit, ham,
salami, and other processed meats, red and white meat
consumption (with questions about meat cooking prac-
tices), pizza, pasta, alcohol, and vitamin/mineral supple-
ments. Additionally, subjects were asked whether they
were on special diets and for what reason. From each lung
cancer case we also collected extensive clinical data,
including histology and grading (ICD-O codes), TNM/
stage (clinical and surgical, AJCC and UICC), imaging and
pathology (surgery, biopsy, and cytology) reports, blood
count and serum tumor markers, chemotherapy or radia-
tion therapy for previous tumors, blood transfusions, and
previous lung diseases with spirometry indexes. From
approximately 10% of the cases, histology slides were
scanned and digital images stored in a large database for
archival, research, and educational purposes.
One of our goals is to integrate genomic and epidemiolog-
ical data with clinical data on therapy outcome and sur-
vival in order to identify genetic factors that affect these
factors. We are currently collecting data from cases on sur-
gical procedures, chemotherapy (type, doses, duration,
cycles, and breaks), radiation therapy (type, duration,
dose, equipments, and breaks), major toxicities, ECOG
performance status, recurrence, smoking after lung cancer
diagnosis, vital status through the Vital Statistic Office,
and death certificates through the Local Health Units
(causes of death are coded following the ICD IX).
Biospecimen collection
Specific laboratory Standard Operating Procedures were
developed (and updated as warranted) within EAGLE to
ensure quality control of every step involved in biospeci-
men collection, processing, transportation, tracking, ship-
ping, and eventual long term storage. Approximately 90%
of cases and 87% of controls donated a blood sample, and
7% of cases and 13% of controls donated buccal rinse
samples (Table 1). Blood samples were transported from
each hospital to the central laboratory within four hours
of phlebotomy by a transportation team established ad
hoc for EAGLE. Blood specimens were processed to obtain
cryopreserved lymphocytes, RBC, granulocytes, DNA,
RNA, whole blood, buffy coat, serum, plasma, and blood
cards. For RNA collection and extraction, we also used
PAX tubes (Paxgene Blood RNA System), which contain a
solution that inhibits RNA degradation and gene induc-
tion as blood is drawn into the tube. Buccal cells obtained
by mouthwash were processed to obtain DNA.
Lung tissue paraffin blocks and slides were collected from
cases that underwent surgery, biopsy, or cytological exam-
ination of the lung tumor (Table 1). Multiple fresh "nor-
mal" lung tissue (adjacent and distant from the malignant
lesion) and tumor samples, frozen in liquid nitrogen
within 20 minutes from excision at surgery, were also col-
lected from 436 cases (about 46% of the surgical cases).
All biospecimens and accompanying forms were labeled
using 2-D bar codes. Biospecimens were shipped accord-
ing to international regulations on alternate weeks follow-
ing different procedures based on biospecimen type, andBMC Public Health 2008, 8:203 http://www.biomedcentral.com/1471-2458/8/203
Page 8 of 10
(page number not for citation purposes)
tracked through a database [18] that stores detailed infor-
mation on sample descriptions, dates, sample transfers,
aliquoting, freezer locations, and material type that is
linked to the repository for easy access and exchange of
laboratory information.
Data management
The study coordination center for EAGLE was established
at the Epidemiology Research Center (EPOCA) of the Uni-
versity of Milan. Ancillary facilities included: 1) a Study
Document Center for the collection and completeness
verification of the computer-assisted questionnaire, and
the scanning and verification of the optical readable forms
and self-administered questionnaires; 2) a Storage and
Processing Laboratory for the collection, processing, stor-
age, and shipping of biospecimens; 3) a Data Processing
Center, for the collection of all data in a central relational
database (MS SQLServer). Data on subjects' accrual and
data/biospecimen collection were regularly transmitted to
the principal investigators at the National Cancer Institute
(NCI), Bethesda, MD through automatically generated
weekly reports. We routinely validated received data by:
comparing information from different sources; assessing
variable range and distribution; evaluating the quality of
biospecimens through specific analyses conducted at the
NCI laboratories on random samples; comparing num-
bers of cases accrued and those reported in the discharge
records of the hospitals during the same time period to
ensure that all consecutive cases were approached for the
study; and verifying completeness of the database through
multiple queries. Upon study completion, we developed
a portal [19] for exchange of data, documents, timelines,
meeting minutes, procedures, and draft manuscripts
among investigators involved in the EAGLE data analyses,
and a website [8] for public access to study design, collab-
orators, descriptive statistics, and publications.
Epidemiological analyses of these and other risk factors
are ongoing, exploiting the richness of molecular data and
the integrative approach described above. For example,
the first analysis of gene expression changes due to
tobacco smoking was recently completed [20].
Discussion
Our study design anticipates configuring all the diverse
classes of data described to address the biological and
clinical challenges posed by lung cancer. We call our
approach integrative to emphasize the inclusion of behav-
ior (e.g., nicotine dependency, smoking intensity, depres-
sion, anxiety, and other psychological traits) and outcome
(e.g., survival from lung cancer) with the traditional
molecular epidemiology framework which uses biomark-
ers to elucidate the biological relationships between expo-
sure, genes, and diseases. Moreover, the integrative
approach allows cross-sectional analyses of multiple fac-
tors (e.g., germline genetic variation, somatic mutations
and gene expression in relation to lung cancer risk or pro-
gression) [21]. This approach provides several key advan-
tages over more fragmented designs: 1) It is highly
efficient and cost effective, since information collected for
one purpose can be leveraged for another, instead of each
goal requiring independent planning, infrastructure and
data collection; 2) Because the design includes diverse
study domains, diverse questions can be addressed that
are inaccessible to more constricted designs. For example,
depression (a behavior) is known to be related to smoking
(an exposure). However, only an integrated design can
establish whether it is also related to lung cancer risk (tak-
ing into account smoking), or lung cancer survival (taking
into account other prognostic factors), or whether genes
related to smoking or depression are the same ones that
influence lung cancer risk [22]. Through the parallel use of
high technology approaches applied to tissue samples,
similar questions can be addressed on the molecular level.
For example, we may assess a gene through a chromo-
somal region, polymorphic variant, expression or methyl-
ation pattern, or its protein product. Eventually all these
approaches can be combined to assess cancer networks; 3)
The integrated approach can identify genes or other fac-
tors that span multiple stages in the development of dis-
ease to its denouement. In general, the major question of
whether the same genes that contribute to the 'cause' of a
cancer also stimulate its progression has been generally
sidestepped by traditional epidemiological study designs.
4) It provides a study crucible where scientists of diverse
disciplines can work in concert to forge a deeper interdis-
ciplinary understanding of the disease etiology.
While tobacco consumption peaked in the United States
in the second third of the 20th century and somewhat later
in Western Europe, worldwide per capita consumption
continues to rise and therefore understanding the precise
molecular basis and susceptibility factors associated with
tobacco carcinogenesis remains a high priority as current
prevention, screening and treatment approaches are all
inadequate.
Opportunities to collaborate
We designed EAGLE knowing that much of its value
would arise from involvement with other investigators,
individually and within consortia. EAGLE is already part
of the International Lung Cancer Consortium (ILCCO)
[23] and is open for collaboration with interested investi-
gators. Given the population-based design, the rigorous
enrollment and quality control strategies, the high
response rate in both lung cancer cases and controls, the
detailed epidemiological data, the excellent quality of
clinical information and diagnostic procedures, and the
ever-growing collection of molecular data, EAGLE will
provide a superb framework for diverse studies and col-BMC Public Health 2008, 8:203 http://www.biomedcentral.com/1471-2458/8/203
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laborative efforts, of which those listed above are just ini-
tial examples.
The EAGLE investigators also want to provide public
access to the data, consistent with appropriate measures to
protect confidentiality. Proposals from outside the study
team for research projects to test specific hypotheses
within EAGLE will be reviewed by an Advisory Board with
rotating membership. Mechanisms and policies to enable
data sharing to interested investigators are posted on the
EAGLE website.
In conclusion, EAGLE is a new large population-based
case-control study that explores the full spectrum of lung
cancer etiology, from smoking addiction to lung cancer
outcome, through cross examination of epidemiological,
molecular, and clinical data. A sharper and more compre-
hensive vision of the complex nature of this disease is
poised to accelerate the emergence of new preventive and
therapeutic strategies with potentially enormous impact
on public health.
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